Codexis (NASDAQ: CDXS) and Methanex (NASDAQ:MEOH) are both industrial products companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, analyst recommendations and dividends.
This table compares Codexis and Methanex’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Methanex pays an annual dividend of $1.32 per share and has a dividend yield of 1.9%. Codexis does not pay a dividend. Methanex pays out 28.0% of its earnings in the form of a dividend.
This is a summary of recent ratings and target prices for Codexis and Methanex, as provided by MarketBeat.com.
||Strong Buy Ratings
Codexis presently has a consensus price target of $14.25, indicating a potential downside of 1.04%. Methanex has a consensus price target of $67.41, indicating a potential downside of 4.65%. Given Codexis’ stronger consensus rating and higher possible upside, analysts clearly believe Codexis is more favorable than Methanex.
Earnings and Valuation
This table compares Codexis and Methanex’s revenue, earnings per share and valuation.
||Earnings Per Share
Methanex has higher revenue and earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Methanex, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
65.9% of Codexis shares are owned by institutional investors. Comparatively, 80.0% of Methanex shares are owned by institutional investors. 11.4% of Codexis shares are owned by company insiders. Comparatively, 1.0% of Methanex shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Volatility and Risk
Codexis has a beta of -1.63, meaning that its stock price is 263% less volatile than the S&P 500. Comparatively, Methanex has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500.
Methanex beats Codexis on 11 of the 16 factors compared between the two stocks.
Codexis, Inc. discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering protein catalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.
Methanex Corporation produces and sells methanol in North America, the Asia Pacific, Europe, and South America. It also purchases and sells methanol produced by others under methanol offtake contracts and on the spot market. The company was founded in 1968 and is headquartered in Vancouver, Canada.
Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.